Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1111 to 1125 of 1553 results for do not do recommendations

  1. ImmunoCAP ISAC 112 for multiplex allergen testing (HTG413)

    Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.

  2. Prontosan for treating acute and chronic wounds (HTG616)

    Evidence-based recommendations on Prontosan for treating acute and chronic wounds.

  3. Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1015)

    Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.

  4. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment (HTG694)

    Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication.

  5. Vortioxetine for treating major depressive episodes (TA367)

    Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.

  6. Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

    Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.

  7. Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

    Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.

  8. Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)

    Evidence-based recommendations on encorafenib (Braftovi) with binimetinib (Mektovi) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults.

  9. Benralizumab for treating severe eosinophilic asthma (TA565)

    Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.

  10. Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (TA850)

    Evidence-based recommendations on amivantamab (Rybrevant) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.

  11. Risdiplam for treating spinal muscular atrophy (TA755)

    Evidence-based recommendations on risdiplam (Evrysdi) for 5q spinal muscular atrophy (SMA) in people of all ages.

  12. Immunosuppressive therapy for kidney transplant in children and young people (TA482)

    Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in children and young people. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).

  13. Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

    Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.

  14. Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation (IPG805)

    Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. This involves implanting a replacement valve inside the faulty native valve.

  15. Baricitinib for treating severe alopecia areata (TA926)

    Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.